ALSO NOTED: Orexigen gets positive Phase II results; AnorMED completes Mozobil enrollment; and much more...
Free newsletter via e-mail
Tools
> AnorMED has completed enrollment in a phase III trial of Mozobil for cancer patients. Release
> Orexigen Therapeutics has revealed positive Phase II results for Excalia, for the treatment of obesity. Excalia is a combination of two centrally-acting medications. Release
> SkinMedica has received FDA approval for Desonate, for treatment for mild to moderate atopic dermatitis. Release
> Bristol-Myers Squibb Company announced that the FDA approved a new 300 mg single capsule formulation of Reyataz for the HIV-1 infection in adults as a part of combination therapy. Report
And Finally... Young people who get a new meningitis shot Menactra could be at higher risk for contracting Guillain-Barre syndrome. Report
SHARE
WITH: